A new mom thought drinking wine was causing strange pain and itching. Months later, a lump in her neck revealed a shocking ...
Patients receiving the tafasitamab combination achieved a median PFS of 22.4 months, compared with 13.9 months for patients receiving placebo with lenalidomide and rituximab. This represents a 57% ...
Eli Lilly Canada, Inc announced today that Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available ...
Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that the U.S. Food and Drug Administration has granted orphan drug ...
Explore the operational challenges and solutions in administering bispecific therapies for follicular lymphoma, focusing on ...
A recent ASH study highlights the impact of CAR T and bispecific therapies on patient time commitment and quality of life in ...
I believe OPKO Health will end 2026 on a high note. Read why I believe OPK stock's risk/reward profile is attractive for long ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results